follow us in feedly
MicroSmallCap

Join Our Community

Facebook

Twitter

RSS

      • Featured
      • Penny Stocks
        • Penny Stocks to Buy
        • Penny Stocks to Sell
        • Robinhood Penny Stocks
      • Robinhood Stocks
        • Top 100
        • Penny Stocks
      • Market Movers
        • Analyst Coverage
        • Earnings Reports
        • Low Float Stocks
        • PDUFA Stage
        • Short Squeeze Stocks
        • Stock Price Target Changes
        • Stocks to Buy
        • Stocks to Sell
      • Sectors
        • Cannabis
        • Consumer
        • Energy
        • Financial
        • Health
        • Mining
        • Tech
      • NewsHub
      HomeAuthorsEd Browne

      Articles by Ed Browne

      Ed Browne
      Ed Browne is a content writer currently living in Vancouver, Canada. He currently writes on the subject of business and finance but has previous experience in human interest articles as well as music reporting. Ed is originally from the UK and spent most of his time working in pubs and bars before graduating and entering a journalistic field.
      Twitter LinkedIn
      Biotechnology

      Novavax Shares Shoot Up Over 50% Amid Promising Trial Developments

      Jan 10 Ed Browne
      Biotech company Novavax (NASDAQ:NVAX) is enjoying a share rise of 59.40% as of 4:00 PM EST today on the heels of announcing encouraging results in an immunization study. This brings their share value up from ... [Read]
      Akers Biosciences
      Health

      Akers Biosciences stock soaring – but why?

      Jan 10 Ed Browne
      It’s pharma fever on the stock market today as the likes of Diffusion Pharmaceuticals (NASDAQ:DFFN) and most notably Pain Therapeutics (NASDAQ:PTIE) have seen stock climb by 42.98% and 114.22% respectively. These heady rises come amid ... [Read]
      Axsome Therapeutics shares drop
      Biotechnology

      Axsome Therapeutics Shares Drop Following ‘Disappointing’ Drug Trial Outcome

      Jan 9 Ed Browne
      It’s a gray morning for Axsome Therapeutics. Shares in the biopharmaceutical company have fallen by -36.94%, bringing the last price to 3.50 as of 2:38 PM EST. The sink comes amid reports that their trial ... [Read]
      WEED Inc.
      Cannabis

      WEED Inc. Stocks Grow by Nearly 40% After Last Week’s Slump

      Jan 9 Ed Browne
      Cannabis shareholders should have their heads in the clouds today as shares in WEED Inc. (OTCMKTS:BUDZ) have grown by nearly 40%, bringing the share price to $12.15 as of 3.50PM. This will relieve company investors ... [Read]
      Vuzix Enjoy Huge Share Spike
      Computer Hardware

      Vuzix Enjoy Huge Share Spike Amid Next-Gen Tech Announcement

      Jan 8 Ed Browne
      The world of Tron may not be too far off as stocks in augmented-reality (AR) wearables firm Vuzix (NASDAQ:VUZI) dart upwards. Prices rose 12.42% today as of 4:00 PM EST, bringing the price per share ... [Read]
      Barnes & Noble
      Consumer

      What’s On the Next Page for Barnes & Noble?

      Jan 5 Ed Browne
      They may be the largest bookseller in the world, but as of today, Barnes & Noble’s (NYSE:BKS) shares are hardly worth writing home about. As of 4:02PM EST, shares in the company plunged a worrying ... [Read]

      Posts pagination

      « 1 … 4 5

      YOU MAY ALSO LIKE

      • Optimi Health
        Optimi Health Has Completed the Largest Legal Harvest of Natural Psilocybin in Canadian History.
        Sep 15 Chinedu Okoro
      • Cardinal Health Reveals Governance Enhancements And Shareholder Value Creation Programs
        Cardinal Health Reveals Governance Enhancements And Shareholder Value Creation Programs
        Sep 9 Adewumi Victor
      • HBO Max Eliminates Approximately 200 'Sesame Street' Episodes
        HBO Max Eliminates Approximately 200 ‘Sesame Street’ Episodes
        Aug 19 Peter Olaoluwapo
      • Blue Water Assumes Administration of Rising River RV Resort and River House
        Blue Water Assumes Administration of Rising River RV Resort and River House
        Aug 19 Peter Olaoluwapo
      • FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
        FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
        Aug 9 Peter Olaoluwapo
      Subscribe & Get The LATEST Stock Pick Alerts
      I want e-mail alerts, updates, and offers and agree to the MicroSmallCap privacy policy.
      Advertise With Us
      • Write for Us
      • Submit Press Release
      • Submit Sponsored Post
      Company
      • Authors
      • Contact Us
      Legal
      • Terms of Use
      • Privacy Policy
      • DMCA Policy
      • Disclaimer
      Follow Us

      Copyright © 2026 | #170 - 422 Richards Street Vancouver, BC, Canada V6B 2Z4 | 1.800.340.9767

      Copyright © 2026 | Terms of Use | Privacy Policy | DMCA | Disclaimer | Authors

      #170 - 422 Richards Street Vancouver, BC, Canada V6B 2Z4 | 1.800.340.9767

      Subscribe & Get FREE Novavax Inc. Email Alerts
      Get FREE Novavax Inc. Email Alerts
      I want e-mail alerts, updates, and offers and agree to the MicroSmallCap privacy policy.
      x